Eli Lilly and Co. has entered a definitive agreement to acquire Dermira, Inc. for approximately $1.1 billion in cash. Dermira is a biopharmaceutical company dedicated to developing new therapies for chronic skin conditions. The acquisition will expand Lilly’s immunology pipeline with the addition of lebrikizumab, a Phase III monoclonal antibody designed to bind IL-13 with high affinity that is being evaluated in moderate-to-severe atopic dermatitis. Lebrikizumab was granted Fast Track ...